Jonathan M Rhodes1, Sreedhar Subramanian2, Paul K Flanagan3, Graham W Horgan4, Kate Martin2, John Mansfield5, Miles Parkes6, Ailsa Hart7, Helen Dallal8, Tariq Iqbal9, Jeffrey Butterworth10, Kate Culshaw11, Christopher Probert2. 1. Henry Wellcome Laboratory, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, Royal Liverpool University Hospital, University of Liverpool, Nuffield Building, Crown Street, Liverpool, L69 3GE, UK. rhodesjm@liverpool.ac.uk. 2. Henry Wellcome Laboratory, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, Royal Liverpool University Hospital, University of Liverpool, Nuffield Building, Crown Street, Liverpool, L69 3GE, UK. 3. Wirral University Teaching Hospital, Birkenhead, UK. 4. Biomathematics and Statistics Scotland, Aberdeen, UK. 5. Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK. 6. Cambridge University Hospitals, Cambridge, UK. 7. St Mark's Hospital, Harrow, UK. 8. James Cook University Hospital, Middlesbrough, UK. 9. Queen Elizabeth Hospital Birmingham, Birmingham, UK. 10. Shrewsbury and Telford Hospital, Shrewsbury, UK. 11. Liverpool Cancer Trials Unit, Liverpool, UK.
Abstract
BACKGROUND: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. AIMS: To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macrophages. METHODS:Adults with moderately active disease (CDAI > 220-450 plus C reactive protein≥ 5 mg/l and/or fecal calprotectin > 250 μg/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks. Primary endpoints were remission (CDAI ≤ 150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding (CDAI fall by > 70) by 10 weeks were invited to crossover onto the alternative therapy. RESULTS:Fifty-nine patients were recruited across 8 sites. Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P = 0.092 at 10 weeks). Withdrawals by 10 weeks due to adverse events were seen in 15 receiving antibiotics/hydroxychloroquine and 6 budesonide. Results including crossover were more promising with 9/24 patients receiving antibiotics/hydroxychloroquine per protocol in remission by 24 weeks. No correlation was seen between response to antibiotics/hydroxychloroquine and ASCA/OmpC antibody status or disease location. CONCLUSION: Overall results with this antibiotic/hydroxychloroquine combination were unimpressive, but long-term remission is seen in some patients and justifies further study.
RCT Entities:
BACKGROUND: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. AIMS: To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macrophages. METHODS: Adults with moderately active disease (CDAI > 220-450 plus C reactive protein ≥ 5 mg/l and/or fecal calprotectin > 250 μg/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks. Primary endpoints were remission (CDAI ≤ 150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding (CDAI fall by > 70) by 10 weeks were invited to crossover onto the alternative therapy. RESULTS: Fifty-nine patients were recruited across 8 sites. Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P = 0.092 at 10 weeks). Withdrawals by 10 weeks due to adverse events were seen in 15 receiving antibiotics/hydroxychloroquine and 6 budesonide. Results including crossover were more promising with 9/24 patients receiving antibiotics/hydroxychloroquine per protocol in remission by 24 weeks. No correlation was seen between response to antibiotics/hydroxychloroquine and ASCA/OmpC antibody status or disease location. CONCLUSION: Overall results with this antibiotic/hydroxychloroquine combination were unimpressive, but long-term remission is seen in some patients and justifies further study.
Authors: Cassandra M Townsend; Claire E Parker; John K MacDonald; Tran M Nguyen; Vipul Jairath; Brian G Feagan; Reena Khanna Journal: Cochrane Database Syst Rev Date: 2019-02-07
Authors: Aditi Kumar; Alexander Cole; Jonathan Segal; Philip Smith; Jimmy K Limdi Journal: Therap Adv Gastroenterol Date: 2022-02-17 Impact factor: 4.409
Authors: Ahmed Abdeen Hamed; Tamer E Fandy; Karolina L Tkaczuk; Karin Verspoor; Byung Suk Lee Journal: Pharmaceutics Date: 2022-03-04 Impact factor: 6.321